ALLR - CONSENSUS CO - Allarity Therapeutics

Allarity Therapeutics, as a biopharmaceutical innovator with robust research potential, leverages IT solutions to personalize therapy, enabling precise forecasting of a patient's response to treatment. This price chart, assisting in the basic asset valuation, recorded a figure of 11.00. Allarity Therapeutics is growing actively, offering cutting-edge targeted therapies combined with a diagnostic tool to identify the patients most sensitive to treatment.

This indicator captures the weighted average valuation of the asset from Wall Street experts, measuring the gap between the market price and the fundamental fair value. By analyzing the history of the consensus target for the stock, investors determine the asset's margin of safety, which is particularly critical for Allarity Therapeutics (ALLR), whose market capitalization depends on the efficiency of its personalized oncology therapy platform and the accuracy of clinical response forecasting.